Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actos Record-breaking Personal Injury Verdict Tied To Drug Revenue

This article was originally published in The Pink Sheet Daily

Executive Summary

Jury awarded $1.5 million in compensatory damages and $9 billion in punitive damages against Takeda and Lilly; judge said jurors could consider Takeda’s destruction of evidence, which included a concern about Actos’ “margin of safety.”

You may also be interested in...



Takeda Shareholders Approve Weber As COO Setting Up Leadership Handover

Christophe Weber wins shareholder approval as chief operating officer at Takeda as expected, setting up a leadership change at Japan’s top, and oldest, drug company over the opposition of some family members.

Rearguard Battle At Takeda Unlikely To Derail Globalization Plans

The planned appointment of Christophe Weber as chief operating officer at Asia’s leading pharmaceutical company has ruffled feathers among traditionalists fearful of change.

Charting The Course Of Product Liability: From Yasmin/Yaz To Actos

Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel